Expansion Opportunities AnaptysBio recently signed an exclusive license agreement with Centessa Group for autoimmune and inflammatory disease treatments, indicating potential expansion opportunities in the biotechnology market.
Strategic Investments Recent investments by Allspring Global Investments and ProFunds Distributors totaling $353K demonstrate investor confidence and potential partnerships for AnaptysBio.
Key Personnel Additions Appointment of John Orwin as Chairman and Rita Jain to the Board of Directors augments AnaptysBio's leadership, potentially fostering new collaborations and market positioning.
Financial Stability With a revenue range of $10M-$50M and funding of $100M, AnaptysBio exhibits financial stability that can support scalability and attract strategic business partnerships.
Market Recognition AnaptysBio's accolades as a BioSpace Best Place to Work and award winner in the small employer category could be leveraged as a competitive edge in attracting top talent and strategic alliances.
62
$10M
501$50M$100M
20
51$10M$50M
70$10M$50M
98$10M$50M
46$10MAnaptysBio uses 8 technology products and services including MySQL, Microsoft Word, Microsoft Outlook, and more. Explore AnaptysBio's tech stack below.
| AnaptysBio Email Formats | Percentage |
| FLast@anaptysbio.com | 97% |
| First.Last@anaptysbio.com | 1% |
| First-Last@anaptysbio.com | 1% |
| FMiddleLast@anaptysbio.com | 1% |
Biotechnology ResearchCalifornia, United States51-200 Employees
AnaptysBio ($ANAB) is a clinical-stage biotechnology company focused on transforming patient health by discovering and developing innovative immunology therapeutics. Our broad portfolio of immune cell modulators includes two checkpoint agonists in clinical-stage development. We are dedicated to making a difference in the lives of people living with autoimmune and inflammatory diseases.
Company Overview
Media & News
Funding & FinancialsAnaptysBio has raised a total of $100M of funding over 6 rounds. Their latest funding round was raised on Aug 14, 2024 in the amount of $100M.
AnaptysBio's revenue is in the range of $10M$50M
Funding & FinancialsAnaptysBio has raised a total of $100M of funding over 6 rounds. Their latest funding round was raised on Aug 14, 2024 in the amount of $100M.
AnaptysBio's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com